Kayla McManus
Psychiatric/Mental Health · Clarksville, TNNPI 1336765411
Payments from drug & device makers
Across 168 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$666
- Neurocrine Biosciences, Inc.$580
- Johnson & Johnson$537
- Supernus Pharmaceuticals, Inc.$475
- Acadia Pharmaceuticals Inc$468
- AbbVie$375
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,298100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 27 | $666 |
| Neurocrine Biosciences, Inc. | 23 | $580 |
| Johnson & Johnson | 21 | $537 |
| Supernus Pharmaceuticals, Inc. | 2 | $475 |
| Acadia Pharmaceuticals Inc | 6 | $468 |
| AbbVie | 32 | $375 |
| Otsuka America Pharmaceutical, Inc. | 17 | $316 |
| E.r. Squibb & Sons, L.L.C. | 11 | $283 |
| Teva Pharmaceuticals USA, Inc. | 13 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $116 |
| Axsome Therapeutics, Inc. | 3 | $92 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Biogen | 1 | $26 |
| Lundbeck LLC | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Indivior Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$457
- NUPLAZID$265
- INVEGA SUSTENNA$150
How this compares
$4,298 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Risperdal ConstaRisperidone Microspheres | 11 | $53,333 |
| VraylarCariprazine Hcl | 13 | $20,697 |
| Oxcarbazepine | 15 | $1,006 |
| Aripiprazole | 12 | $831 |
| Trazodone Hcl | 46 | $710 |
| Hydroxyzine Pamoate | 22 | $681 |
| Duloxetine Hcl | 23 | $533 |
| Hydroxyzine Hcl | 23 | $435 |
| Risperidone | 24 | $429 |
| Lorazepam | 13 | $356 |
| Escitalopram Oxalate | 18 | $244 |
| Buspirone Hcl | 11 | $212 |
| Bupropion XlBupropion Hcl | 22 | $198 |
| Amitriptyline Hcl | 18 | $192 |
| Propranolol Hcl | 15 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRisperdal Consta | $537 | $53,33311 claims |
| AbbVieVraylar | $375 | $20,69713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Clarksville
- Stacy DycusClarksville$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
- Kristal HurstBlaine$260K
- Kaitlynn EarlsGreeneville$228K
- Tory WoodardCookeville$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.